{"id":383640,"date":"2025-08-29T23:09:12","date_gmt":"2025-08-29T23:09:12","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/383640\/"},"modified":"2025-08-29T23:09:12","modified_gmt":"2025-08-29T23:09:12","slug":"clarityx-expands-leadership-in-precision-health-with-national-launch-of-thrive-and-clear-genetic-wellness-tests-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/383640\/","title":{"rendered":"ClarityX\u00ae Expands Leadership in Precision Health with National Launch of Thrive\u2122 and Clear\u2122 Genetic Wellness Tests"},"content":{"rendered":"

Miami, FL – August 29, 2025 –<\/strong>\u00a0ClarityX\u00ae, a leading innovator in direct-to-patient genetic testing and precision health, today announced the national launch of its new genetic wellness portfolio, featuring Thrive\u2122, a comprehensive nutrigenomics test, and Clear\u2122, an advanced dermatogenomics test for skin health.<\/p>\n

\"\"<\/p>\n

Leveraging its nationally recognized pharmacogenetic (PGx) testing platform, ClarityX\u00ae<\/a> is expanding into a comprehensive portfolio of science-backed solutions for proactive longevity and wellness management. By combining nutrigenomics and dermatogenomics with its existing medication optimization solutions, the company is uniquely positioned to support the full spectrum of personalized wellness.<\/p>\n

This expansion marks a significant milestone in ClarityX\u00ae\u2019s mission to deliver science-backed, clinically relevant insights that empower individuals to live longer, healthier lives. The new offerings position ClarityX\u00ae at the forefront of the rapidly growing longevity market, underscoring the company\u2019s expanding influence in precision wellness.<\/p>\n

\u201cWith Thrive\u2122 and Clear\u2122, ClarityX\u00ae is setting a new standard for personalized wellness,\u201d said Andres Benzaquen, CEO of ClarityX\u00ae. \u201cThese products are more than tests; they’re the foundation of a data-driven health platform designed to help people make better decisions about their nutrition, skincare, and overall longevity. We believe that genetic insights should be clear, actionable, and accessible to everyone, and this launch is a major step toward that vision.\u201d<\/p>\n

Thrive\u2122 analyzes over 40 genetic traits related to nutrition, metabolism, and lifestyle, delivering personalized, evidence-based recommendations for diet and wellness optimization. From vitamin utilization (such as folate and Vitamin D) to sensitivities to lactose, caffeine, and alcohol, Thrive\u2122 provides an actionable blueprint for better health and performance.<\/p>\n

Clear\u2122 offers an in-depth analysis of genetic factors influencing skin health, including collagen production, elasticity, aging markers, and sun sensitivity. By revealing an individual\u2019s unique skin profile, Clear\u2122 empowers the creation of truly customized skincare regimens that address specific genetic needs.<\/p>\n

To learn more about the Thrive\u2122 and Clear\u2122 Genetic Wellness Tests, please visit https:\/\/clarityxdna.com\/<\/a>.<\/p>\n

About ClarityX\u00ae<\/strong><\/p>\n

Based in Miami, Florida, ClarityX\u00ae is a healthcare technology leader specializing in patient-focused genetic testing. ClarityX\u00ae’s portfolio spans pharmacogenetics and wellness genetic testing, providing accessible, affordable, and clinically actionable insights that empower individuals to make smarter, data-driven decisions about their medications and overall health.<\/p>\n

Media Contact
Company Name:<\/strong> ClarityX
Contact Person:<\/strong> Greisy Schiling
Email:<\/strong>Send Email<\/a>
Phone:<\/strong> 800-921-8957
Country:<\/strong> United States
Website:<\/strong>https:\/\/clarityxdna.com\/<\/a>
\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"Miami, FL – August 29, 2025 –\u00a0ClarityX\u00ae, a leading innovator in direct-to-patient genetic testing and precision health, today…\n","protected":false},"author":2,"featured_media":383641,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[51,3085,1700,474,6614,267,6620,6615,6616,3151,4041,70,6619,6617,6618,6621,16,15],"class_list":{"0":"post-383640","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-business","9":"tag-business-news","10":"tag-economy","11":"tag-finance","12":"tag-financial-information","13":"tag-genetics","14":"tag-getnews","15":"tag-investing","16":"tag-investor","17":"tag-market-news","18":"tag-press-releases","19":"tag-science","20":"tag-sedar","21":"tag-stock-research","22":"tag-stock-valuation","23":"tag-the-globe-and-mail","24":"tag-uk","25":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115114578317135266","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/383640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=383640"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/383640\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/383641"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=383640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=383640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=383640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}